Increased Risk of Mycobacterial Infection With Immune Checkpoint Inhibitors
Using FAERS, study researchers identified reported cases of tuberculosis and atypical mycobacterial infection in patients who received ICIs.
Using FAERS, study researchers identified reported cases of tuberculosis and atypical mycobacterial infection in patients who received ICIs.
Interleukin 17 may be a therapeutic target worth investigating for patients with lung cancer and SARS-CoV-2 infection, existing literature suggests.